MergerMay 18, 2026, 09:17 AM
XOMA Royalty Amends Merger Agreement with Ligand, Adds HoldCo
AI Summary
XOMA Royalty Corporation, Ligand Pharmaceuticals Incorporated, and Flex Merger Sub, Inc. entered into Amendment No. 1 to their Agreement and Plan of Merger on May 16, 2026. This amendment formally adds XOMA Royalty Holdings Corporation (HoldCo), a newly formed wholly-owned subsidiary of XOMA Royalty, as a party to the Merger Agreement. HoldCo was established to facilitate a holding company reorganization, which is a step in the previously announced merger where Flex Merger Sub will merge into HoldCo, making HoldCo a wholly-owned subsidiary of Ligand.
Key Highlights
- Amendment No. 1 to the Agreement and Plan of Merger was executed on May 16, 2026.
- The amendment adds XOMA Royalty Holdings Corporation (HoldCo) as a party to the Merger Agreement.
- HoldCo is a newly formed, wholly-owned subsidiary of XOMA Royalty, created for a holding company reorganization.
- The original Merger Agreement was entered into on April 27, 2026, with Ligand Pharmaceuticals and Flex Merger Sub.
- The merger involves Flex Merger Sub merging into HoldCo, with HoldCo surviving as a wholly-owned subsidiary of Ligand.
- The amendment updates references to Nevada Revised Statutes and clarifies terms regarding the surviving corporation.
Price Impact
More from XOMA